GlassScriptPhysician profile
Michael S Wehmann
NPI 1154632875
$2,366.69
in general payments reported to CMS, 2019-2025
24 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $195 · 2021: $132 · 2022: $373 · 2023: $349 · 2024: $538 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $675.98 | 2019-2025 | Unity, Clareon, Argos |
| Bausch & Lomb Americas INC. | $205.49 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $194.79 | 2019-2025 | Cequa |
| Notal Vision, INC. | $172.56 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $143.09 | 2019-2024 | Tecnis Iol |
| Rxsight INC | $121.28 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Abbvie INC. | $120.92 | 2022-2025 | Alphagan P, Vuity, Lumigan |
| Tarsus Pharmaceuticals, INC. | $111.38 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $86.21 | 2024-2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $60.63 | 2019-2023 | |
| Oyster Point Pharma, INC. | $56.56 | 2025 | Tyrvaya, Ryzumvi |
| Thea Pharma INC. | $43.94 | 2025 | Iyuzeh |
| Horizon Therapeutics Plc | $43.53 | 2020-2022 | |
| Eyevance Pharmaceuticals LLC | $40.96 | 2019-2022 | |
| Allergan, INC. | $38.86 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $37.45 | 2019-2021 | |
| New World Medical,INC. | $36.65 | 2022-2024 | Kahook Dual Blade, Streamline, Clearpath |
| Kala Pharmaceuticals, INC. | $36.48 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $36.24 | 2020-2021 | |
| Shire North American Group INC | $27.09 | 2019 | |
| Glaukos Corporation | $20.99 | 2022 | |
| Biotissue Holdings INC. | $19.44 | 2019 | |
| Sight Sciences, INC. | $18.82 | 2023 | Omni Surgical System |
| Apellis Pharmaceuticals, INC. | $17.35 | 2024 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wehmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.